Pluristem Therapeutics' (PSTI) PLX-PAD Receives FDA Orphan Drug Designation
Tweet Send to a Friend
Pluristem Therapeutics Inc. (Nasdaq: PSTI) announced that the U.S. Food and Drug Administration has granted the Company’s PLX-PAD cells Orphan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE